CH 223191: A Next-Generation AhR Antagonist for Advanced Dioxin Toxicity Research

Introduction

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor at the heart of environmental toxicology research, mediating the cellular response to environmental contaminants such as dioxins, polychlorinated biphenyls, and polycyclic aromatic hydrocarbons. Dioxin toxicity, most notably exemplified by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), is a pressing concern in toxicology of environmental contaminants, given its ability to induce hepatic toxicity, immunosuppression, and carcinogenesis through AhR activation. Precise modulation of AhR activity is essential for elucidating the toxicology of aryl hydrocarbon receptor signaling and developing effective strategies for dioxin toxicity mitigation.

CH 223191 (CAS 301326-22-7) has emerged as one of the most selective and potent AhR antagonists available, offering researchers an advanced tool for dissecting the transcription factor modulation underlying dioxin-induced pathologies. This article provides a comprehensive analysis of CH 223191’s mechanism of action, its application in hepatic toxicity models, and its unique role in environmental toxicology research, with an emphasis on mechanistic studies that extend beyond traditional toxicology endpoints.

Mechanism of Action of CH 223191 in AhR Signaling Pathway Inhibition

Specificity and Potency as an AhR Antagonist

CH 223191 is a small-molecule AhR antagonist that exhibits exceptional selectivity. It inhibits AhR-mediated transcriptional activation—specifically the dioxin response element-driven gene expression—induced by prototypic ligands such as TCDD. In cell-based assays, CH 223191 displays an IC₅₀ of approximately 30 nM, underscoring its high potency in transcription factor inhibition. Unlike earlier broad-spectrum inhibitors, CH 223191 does not exhibit significant off-target activity against other nuclear receptors, making it a preferred choice for dioxin toxicity mechanism studies and hepatic toxicity research.

Molecular Mechanism and Impact on Cytochrome P450 1A1 Expression

Upon ligand binding, the AhR translocates to the nucleus and forms a heterodimer with ARNT (AhR nuclear translocator), initiating transcription of target genes, including CYP1A1—a gene central to xenobiotic metabolism and a biomarker for AhR activation. CH 223191 competitively inhibits AhR, thus preventing TCDD-induced upregulation of CYP1A1 at both mRNA and protein levels. This cytochrome P450 1A1 expression inhibition translates into reduced metabolic activation of pro-toxicants and diminished production of reactive oxygen species, two key processes implicated in hepatic toxicity and systemic toxic effects of TCDD.

In Vivo Efficacy: Mitigation of Dioxin-Induced Toxicity

In animal models, CH 223191 demonstrates robust efficacy in dioxin toxicity mitigation. It significantly attenuates TCDD-induced hepatic injury, as evidenced by reduction in plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and protects against TCDD-induced weight loss. This positions CH 223191 as a reference AhR antagonist for dioxin toxicity research and a valuable probe for unraveling the toxicology of aryl hydrocarbon receptor signaling in vivo.

Advanced Applications of CH 223191 in Environmental Toxicology Research

Probing the Transcriptional Network of AhR

Beyond classical hepatic toxicity models, CH 223191 is instrumental in dissecting the broader transcriptional network modulated by AhR. This includes regulation of genes involved in immune modulation, oxidative stress response, and epithelial differentiation. By enabling selective AhR-mediated transcription inhibition, CH 223191 provides a unique lens for exploring non-canonical AhR pathways and their crosstalk with microbiota-derived metabolites, as recently highlighted in studies of intestinal health and disease.

Mechanistic Insights from Recent Research: The Microbiota–Tryptophan Metabolism–AhR Axis

Emerging research underscores the multifaceted role of AhR in intestinal homeostasis, notably in the context of ulcerative colitis and gut barrier repair. A seminal study by Li et al. (2026) (Chinese Medicine 21:33) elucidates how microbiota-driven tryptophan metabolites act as endogenous AhR agonists, promoting intestinal stem cell differentiation and mucosal integrity. Crucially, the beneficial effects of herbal interventions such as Huangqin decoction were abrogated by AhR inhibition, directly implicating the receptor in these protective mechanisms. Utilization of AhR antagonists like CH 223191 in such models allows researchers to parse the causal relationships between microbiota metabolism, AhR activation, and epithelial regeneration—offering mechanistic insights that extend far beyond traditional toxicology endpoints.

Cytochrome P450 1A1 Expression Modulation in Disease Models

CH 223191’s capacity for cytochrome P450 1A1 expression modulation is not only pivotal in environmental toxicology research but also in studying metabolic diseases, carcinogenesis, and immune homeostasis. By precisely inhibiting this enzyme’s induction, researchers can decouple the effects of AhR signaling from downstream oxidative stress and metabolic reprogramming, providing clarity in complex disease models where multiple signaling pathways converge.

Comparative Analysis: CH 223191 Versus Alternative AhR Inhibitors

Advantages Over Non-Selective Inhibitors

Historically, studies of AhR function employed broad-spectrum antagonists or genetic knockouts, each with inherent limitations. Non-selective inhibitors often exhibit off-target effects, compromising data interpretation, while genetic approaches may induce compensatory signaling or developmental artifacts. In contrast, CH 223191, with its high specificity and nanomolar potency for AhR, enables acute and reversible inhibition, facilitating temporal control in both in vitro and in vivo contexts. This makes it particularly advantageous for dioxin toxicity mechanism studies where precise modulation of transcription factor activity is required.

Integration with Next-Generation Toxicology Platforms

CH 223191 is compatible with advanced toxicology technologies such as transcriptomics, proteomics, and high-content imaging. Its defined pharmacological profile and validated purity (>98% by HPLC and NMR, as provided by APExBIO) ensure reproducibility across platforms, making it an essential component in multi-omics studies of the toxicology of environmental contaminants.

Technical Considerations for Laboratory Use

• Chemical Properties: CH 223191 is a solid compound (molecular weight 333.39, chemical formula C₁₉H₁₉N₅O) with high solubility in DMSO (≥33.3 mg/mL) and ethanol (≥2.31 mg/mL), but it is insoluble in water.
• Storage Guidelines: For optimal stability, store at -20°C. Long-term storage of solutions is discouraged; use prepared solutions promptly.
• Purity: Each batch is validated for >98% purity by HPLC and NMR, as ensured by APExBIO.

For detailed product handling and procurement, visit the official CH 223191 product page.

Expanding the Research Frontier: From Hepatic Toxicity to Regenerative Medicine

From Dioxin Toxicity Models to Stem Cell and Barrier Function Studies

While CH 223191 is a mainstay in hepatic toxicity models—serving as a reference AhR antagonist for dioxin toxicity research—its utility is expanding into new frontiers. Recent studies, such as those by Li et al., demonstrate that selective AhR inhibition can dissect the balance between stem cell renewal and differentiation in the gut, linking environmental exposure to regenerative processes. This positions CH 223191 as a versatile probe not only for toxicology but also for studying stem cell biology, mucosal immunology, and host-microbiome interactions.

Interlinking with Broader Toxicology Content

This article builds upon and extends the existing literature by providing a mechanistic and application-driven perspective on the use of CH 223191. While previous articles have focused primarily on the cataloging of AhR ligands or general toxicology methodologies, here we emphasize how CH 223191 enables advanced dissection of the AhR signaling pathway and its intersection with microbiota-derived metabolites and epithelial regeneration. By focusing on both traditional and emerging applications—including the modulation of cytochrome P450 1A1 expression and the study of the microbiota–tryptophan–AhR axis—this article provides a more holistic and forward-looking analysis.

Conclusion and Future Outlook

CH 223191 is redefining the landscape of AhR antagonist research, offering precise, reproducible, and versatile inhibition of the aryl hydrocarbon receptor for toxicology of environmental contaminants and beyond. Its role in clarifying the mechanisms of dioxin toxicity, hepatic injury, and the broader impacts of transcription factor modulation continues to grow, especially as research delves into the interplay between the gut microbiome, tryptophan metabolism, and tissue regeneration. As advanced models of disease and multi-omics technologies become increasingly prevalent, CH 223191—available from APExBIO—will remain an indispensable tool for both established and emerging lines of investigation.

For researchers seeking a robust and validated AhR signaling pathway inhibitor for cutting-edge dioxin toxicity mechanism study, CH 223191 offers unparalleled specificity, reproducibility, and scientific utility.